Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Camilla Rogers

Special Counsel

London +44 20 7067 2292

  • About
  • Representative Matters
  • Credentials
  • About

    Camilla Rogers is special counsel based in Covington’s London office.

    Camilla advises clients on a broad range of corporate transactional and commercial matters, including mergers and acquisitions, venture capital, global restructuring projects (including pre-merger separations and post-merger integrations) and general corporate advisory and strategic work.

    Camilla acts for investors and companies at all stages of development across a broad range of industries. She has particular experience advising on deals and reorganisations in the, biotechnology, technology and life sciences sectors, and her practice is global, covering EMEA in particular.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Advising UK digital product agency, Somo Global, on its sale to CI&T, a Brazilian digital specialist company listed on NYSE.
    • Representing US biotechnology company, Odyssey Therapeutics, on its acquisition of UK quantum machine learning drug discovery company, Rahko.
    • Advising Merck & Co., Inc. on its global separation in preparation for the $9 billion spin-off of its Organon business.
    • Advising Merck & Co., Inc. on an ongoing basis on global post-merger integrations of Schering-Plough Corporation and Cubist Pharmaceuticals.
    • Advising BenevolentAI, a global leader in the development and application of AI for scientific innovation, on an £80 million equity investment by new and existing investors, including Woodford Investment Management.
    • Advising BenevolentAI on its acquisition of Proximagen Limited, a Cambridge, UK-based drug discovery and development company.
    • Advising the syndicate of investors, including Touchstone Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Woodford Patient Capital Trust, on both their £31.5 million Series A and £17-27 million Series B investments in Inivata Limited, a clinical cancer genomics company employing the precision of ctDNA analysis to improve personalized healthcare in oncology.

    • Representing AstraZeneca in connection with its entry into a commercialization agreement with Aspen Global Incorporated for rights to its global anesthetics portfolio outside the U.S.
    • Advising Touchstone Innovations on various investments, including portfolio companies ApcinteX, Inivata and Precision Ocular.
    • Advising AstraZeneca on its acquisition of the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.
    • Acting for the Dubai-based family office of a high net worth individual on the disposal of a minority stake in an African telecommunications company.
    • Advising an LSE-listed industrial services company focused in the energy and natural resources sectors on the refinancing of its principal facilities under a revolving credit facility arranged by a syndicate of leading banks.
    • Advising various international companies across a range of sectors on incorporating subsidiary companies and representative branches within onshore Dubai and in the Dubai Free Zones.

    Areas of Expertise

  • Credentials
    Education
    • BPP Law School, London, L.P.C., 2011
        • Distinction
    • BPP Law School, London, G.D.L., 2010
        • Commendation
    • University of Cambridge, 2009
        • MA (Cantab)
        • Classics
    Bar Admissions
    • Solicitor of the Senior Courts of England and Wales
    Previous Experience
    • Corporate associate in the Dubai office of an international law firm.

    Areas of Expertise

News and Insights

Events